Monoclonal antibodies are exquisitely specific for target antigen, and, given the established expression of GPC-1 in malignancy, including GBM, and the lack of GPC-1 expression seen in normal tissue, molecular targeting using Miltuximab® may afford a specificity advantage over the use of 5-ALA. Here, GPC1 is linked to glioblastoma.